Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
← catalyst calendarNCT07146113 · readout in 315 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Suspended
Study type
Observational
Enrollment
400estimated
Sites
16
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
As a part of planned reassessment for the current period, a decision has been made to prioritize, optimize, and reallocate resources. As a result, enrollment and other study activities have been temporarily halted.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Primary outcomes
what the primary-completion date above is the date OFProportion of patients received any ADT
measured 24 months
Proportion of patients received ADT by each type and by each drug
measured 24 months
Proportion of patients received first generation antiandrogens
measured 24 months
Proportion of patients received ARPI at mHSPC
measured 24 months
Proportion of patients received any chemotherapy at mHSPC
measured 24 months
Duration of chemotherapy
measured 24 months
Proportion of patients received radiation therapy
measured 24 months
Proportion of patients with each radiation area
measured 24 months
Proportion of patients underwent surgery at mHSPC stage
measured 24 months
Proportion of patients received triplet therapy
measured 24 months
Proportion of patients with PTEN loss by IHC
measured 24 months
Number of Chemotherapy Cycles
measured 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed